Table 4.
Crude adverse event rate in 3 yr of follow-up by sex and eGFR at study entry and Fine and Gray SHRs of men vs. women for dialysis, transplant, and all-cause pre-KRT deaths throughout 3 yr of follow-up
| Parameter | Men |
Women |
||||
|---|---|---|---|---|---|---|
| Overall | Stage 3 | Stage 4/5 | Overall | Stage 3 | Stage 4/5 | |
| Patients, n | 4811 | 1886 | 2925 | 3426 | 1117 | 2309 |
| Median follow-up time, yr | 2.7 | 3.0 | 2.0 | 2.5 | 3.0 | 2.0 |
| Adverse event, n (rate, per 100 patient-yr) | ||||||
| Hospitalizationsa | 1240 (17.6) | 550 (14.4) | 690 (21.3) | 762 (16.7) | 270 (12.7) | 492 (20.2) |
| KRTb | 842 (8.3) | 57 (1.2) | 785 (14.2) | 483 (6.8) | 25 (0.9) | 458 (10.3) |
| Dialysis | 785 (7.7) | 53 (1.1) | 732 (13.2) | 451 (6.3) | 22 (0.8) | 429 (9.7) |
| Kidney transplantation | 61 (0.6) | 4 (0.1) | 57 (1.0) | 33 (0.5) | 3 (0.1) | 30 (0.7) |
| Death before KRT | 515 (5.1) | 156 (3.3) | 359 (6.5) | 300 (4.2) | 61 (2.3) | 239 (5.4) |
| Deathc | 612 (6.0) | 162 (3.5) | 450 (8.1) | 358 (5.0) | 64 (2.4) | 294 (6.6) |
| Fine and Gray SHR (95% CI) | Pre-KRT death | Dialysis | Transplant |
|---|---|---|---|
| Model 1 | 1.20 (0.97–1.47) | 1.49 (1.25–1.78) | 1.16 (0.65–2.07) |
| Model 2 | 1.25 (1.02–1.54) | 1.51 (1.27–1.80) | 1.31 (0.73–2.36) |
| Model 3 | 1.25 (1.02–1.53) | 1.50 (1.26–1.78) | 1.35 (0.75–2.44) |
| Model 4 | 1.15 (0.94–1.42) | 1.47 (1.23–1.76) | 1.44 (0.78–2.66) |
| Model 5 | 1.22 (1.00–1.50) | 1.36 (1.14–1.63) | 1.25 (0.69–2.27) |
| Model 6 | 1.14 (0.92–1.40) | 1.32 (1.10–1.59) | 1.44 (0.76–2.74) |
| Model 7 | 1.15 (0.93–1.42) | 1.50 (1.25–1.80) | 1.53 (0.79–2.94) |
| Model 8 | 1.14 (0.93–1.40) | 1.44 (1.20–1.73) | 1.41 (0.69–2.86) |
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; KRT, kidney replacement therapy; SHR, subdistribution hazard ratio.
Models stratified by CKD stage at study entry and accounting for facility clustering.
Model 1: Unadjusted.
Model 2: Adjusted for age, Black race (equals model A [abstract]).
Model 3: Model 2 + diabetes comorbidity.
Model 4: Model 2 + cardiovascular disease (including coronary artery disease, cerebrovascular disease, congestive heart failure, and other cardiovascular diseases).
Model 5: Model 2 + albuminuria.
Model 6: Model 2 + diabetes comorbidity, cardiovascular disease, albuminuria (equals model B [abstract]).
Model 7: Model 6 + first eGFR in first 12 mo after study enrollment as baseline eGFR + eGFR slope in first 12 mo after study enrollment as continuous variable (equals model C [abstract]).
Model 8: Model 6 + last eGFR in first 12 mo after study enrollment as baseline eGFR + eGFR slope in first 12 mo after study enrollment as continuous variable.
Hospitalization data are not available for Germany.
Includes dialysis and kidney transplantation.
Includes death occurred within 1 yr after patient’s departure.